Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NASDAQ:EQIX NYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$210.54-0.1%$210.27$180.25▼$244.81$371.72B0.326.84 million shs5.36 million shsEQIXEquinix$1,059.44-1.9%$1,026.42$710.52▼$1,128.68$104.49B1.01569,078 shs453,741 shsJNJJohnson & Johnson$226.81-1.7%$235.13$149.04▼$251.71$545.74B0.277.58 million shs12.16 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie0.00%+4.62%+0.74%-9.08%+18.75%EQIXEquinix0.00%-1.18%-1.07%+10.80%+23.30%JNJJohnson & Johnson0.00%+2.55%-3.31%-6.81%+54.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$210.54-0.1%$210.27$180.25▼$244.81$371.72B0.326.84 million shs5.36 million shsEQIXEquinix$1,059.44-1.9%$1,026.42$710.52▼$1,128.68$104.49B1.01569,078 shs453,741 shsJNJJohnson & Johnson$226.81-1.7%$235.13$149.04▼$251.71$545.74B0.277.58 million shs12.16 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie0.00%+4.62%+0.74%-9.08%+18.75%EQIXEquinix0.00%-1.18%-1.07%+10.80%+23.30%JNJJohnson & Johnson0.00%+2.55%-3.31%-6.81%+54.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.88Moderate Buy$253.4320.37% UpsideEQIXEquinix 2.97Moderate Buy$1,143.607.94% UpsideJNJJohnson & Johnson 2.74Moderate Buy$253.0411.57% UpsideCurrent Analyst Ratings BreakdownLatest ABBV, EQIX, and JNJ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026ABBVAbbVie EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$235.005/14/2026ABBVAbbVie Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$294.00 ➝ $298.005/13/2026JNJJohnson & Johnson Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Outperform5/13/2026JNJJohnson & Johnson Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$265.005/7/2026EQIXEquinix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)5/7/2026EQIXEquinix MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$1,165.00 ➝ $1,200.005/5/2026EQIXEquinix Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1,207.005/1/2026EQIXEquinix Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$1,215.005/1/2026ABBVAbbVie GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$249.005/1/2026EQIXEquinix Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$1,173.00 ➝ $1,186.004/30/2026EQIXEquinix CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform(Data available from 5/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$62.82B5.92$15.16 per share13.89($3.74) per share-56.29EQIXEquinix$9.22B11.34$34.79 per share30.45$144.94 per share7.31JNJJohnson & Johnson$94.19B5.80$14.12 per share16.06$33.73 per share6.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.23B$2.03103.7112.920.735.79%-576.45%13.39%7/30/2026 (Estimated)EQIXEquinix$1.35B$14.4573.3225.781.9915.07%10.03%3.60%7/29/2026 (Estimated)JNJJohnson & Johnson$26.80B$8.6526.2218.032.2221.83%32.60%13.29%7/15/2026 (Estimated)Latest ABBV, EQIX, and JNJ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/29/2026Q1 2026ABBVAbbVie$2.59$2.65+$0.06$0.39$14.72 billion$15.00 billion4/29/2026Q1 2026EQIXEquinix$4.30$10.79+$6.49$4.20$2.52 billion$2.44 billion4/14/2026Q1 2026JNJJohnson & Johnson$2.68$2.70+$0.02$2.14$23.60 billion$24.06 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.923.29%+6.80%340.89%53 YearsEQIXEquinix$20.641.95%+12.01%142.84%10 YearsJNJJohnson & Johnson$5.202.29%+5.25%60.12%64 YearsLatest ABBV, EQIX, and JNJ DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2026EQIXEquinixquarterly$5.161.94%5/20/20265/20/20266/17/20264/14/2026JNJJohnson & Johnsonquarterly$1.342.23%5/26/20265/26/20266/9/20262/19/2026ABBVAbbViequarterly$1.733.32%4/15/20264/15/20265/15/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVieN/A0.800.56EQIXEquinix1.391.181.18JNJJohnson & Johnson0.461.030.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%EQIXEquinix94.94%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.06%EQIXEquinix0.27%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie57,0001.77 billion1.77 billionOptionableEQIXEquinix13,71698.62 million98.36 millionOptionableJNJJohnson & Johnson138,2002.41 billion2.40 billionOptionableABBV, EQIX, and JNJ HeadlinesRecent News About These CompaniesNanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer2 hours ago | finance.yahoo.comWealthPlan Investment Management LLC Reduces Stock Holdings in Johnson & Johnson $JNJMay 17 at 7:16 AM | marketbeat.comLeuthold Group LLC Invests $6.62 Million in Johnson & Johnson $JNJMay 17 at 6:49 AM | marketbeat.comJohnson & Johnson $JNJ Stock Position Increased by L & S Advisors IncMay 17 at 6:41 AM | marketbeat.comJohnson & Johnson $JNJ Shares Bought by iA Global Asset Management Inc.May 17 at 6:16 AM | marketbeat.comSaratoga Research & Investment Management Has $95.24 Million Stock Position in Johnson & Johnson $JNJMay 17 at 6:07 AM | marketbeat.comCanada Post Corp Registered Pension Plan Acquires 7,871 Shares of Johnson & Johnson $JNJMay 17 at 4:29 AM | marketbeat.comJohnson & Johnson $JNJ Shares Purchased by ARS Investment Partners LLCMay 17 at 3:38 AM | marketbeat.comLawood & Co. Makes New $3.28 Million Investment in Johnson & Johnson $JNJMay 16 at 6:39 AM | marketbeat.comFinancial Security Advisor Inc. Sells 22,920 Shares of Johnson & Johnson $JNJMay 16 at 6:29 AM | marketbeat.comStephens Inc. AR Sells 4,786 Shares of Johnson & Johnson $JNJMay 16 at 6:21 AM | marketbeat.comJohnson & Johnson $JNJ Shares Acquired by Lockheed Martin Investment Management Co.May 16 at 6:11 AM | marketbeat.comSwedbank AB Buys 117,623 Shares of Johnson & Johnson $JNJMay 16 at 4:49 AM | marketbeat.comQuent Long Short Global Small Cap Fund LP Buys Shares of 8,343 Johnson & Johnson $JNJMay 16 at 4:48 AM | marketbeat.comDNB Asset Management AS Reduces Stock Holdings in Johnson & Johnson $JNJMay 16 at 4:32 AM | marketbeat.comJohnson & Johnson $JNJ Shares Bought by Commerzbank Aktiengesellschaft FIMay 16 at 4:31 AM | marketbeat.comAustralianSuper Pty Ltd Sells 70,893 Shares of Johnson & Johnson $JNJMay 16 at 4:21 AM | marketbeat.comJohnson & Johnson $JNJ Shares Acquired by Applied Finance Capital Management LLCMay 16 at 3:31 AM | marketbeat.comAlphaCore Capital LLC Grows Stock Position in Johnson & Johnson $JNJMay 16 at 3:17 AM | marketbeat.comAMJ Financial Wealth Management Acquires 5,427 Shares of Johnson & Johnson $JNJMay 16 at 3:07 AM | marketbeat.comANTIPODES PARTNERS Ltd Has $24.18 Million Position in Johnson & Johnson $JNJMay 16 at 3:07 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?By Thomas Hughes | April 29, 2026The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the BeatBy Jessica Mitacek | May 2, 2026ABBV, EQIX, and JNJ Company DescriptionsAbbVie NYSE:ABBV$210.54 -0.23 (-0.11%) Closing price 05/15/2026 03:59 PM EasternExtended Trading$210.80 +0.26 (+0.12%) As of 05/15/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Equinix NASDAQ:EQIX$1,059.44 -20.24 (-1.87%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$1,057.70 -1.74 (-0.16%) As of 05/15/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Equinix (Nasdaq: EQIX) is the world's digital infrastructure company . Digital leaders harness Equinix's trusted platform to bring together and interconnect foundational infrastructure at software speed. Equinix enables organizations to access all the right places, partners and possibilities to scale with agility, speed the launch of digital services, deliver world-class experiences and multiply their value, while supporting their sustainability goals.Johnson & Johnson NYSE:JNJ$226.81 -3.99 (-1.73%) Closing price 05/15/2026 03:59 PM EasternExtended Trading$226.85 +0.04 (+0.02%) As of 05/15/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In Robinhood, SoFi, and Webull Are Telling Very Different Stories Viking Sails to All-Time Highs—Fundamentals Signal More to Come Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
